Vericel Corporation (VCEL) Can’t Be More Safe. Trades Significantly Higher

March 14, 2018 - By Vivian Park

The stock of Vericel Corporation (NASDAQ:VCEL) is a huge mover today! The stock increased 2.64% or $0.3 during the last trading session, reaching $11.65. About 1.13M shares traded or 15.95% up from the average. Vericel Corporation (NASDAQ:VCEL) has declined 10.47% since March 14, 2017 and is downtrending. It has underperformed by 27.17% the S&P500.
The move comes after 5 months positive chart setup for the $406.68 million company. It was reported on Mar, 14 by We have $12.00 PT which if reached, will make NASDAQ:VCEL worth $12.20M more.

Vericel Corporation (NASDAQ:VCEL) Ratings Coverage

Among 4 analysts covering Vericel (NASDAQ:VCEL), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Vericel had 12 analyst reports since March 11, 2016 according to SRatingsIntel. BTIG Research maintained the shares of VCEL in report on Tuesday, November 7 with “Buy” rating. The company was maintained on Wednesday, August 9 by Piper Jaffray. The firm has “Neutral” rating given on Tuesday, April 5 by Bank of America. The firm earned “Buy” rating on Tuesday, October 3 by Piper Jaffray. Piper Jaffray initiated it with “Overweight” rating and $6 target in Thursday, December 22 report. Needham maintained it with “Buy” rating and $9 target in Wednesday, November 9 report. The stock of Vericel Corporation (NASDAQ:VCEL) has “Buy” rating given on Friday, March 11 by Needham. BTIG Research maintained the stock with “Buy” rating in Wednesday, August 9 report. BTIG Research maintained Vericel Corporation (NASDAQ:VCEL) on Monday, March 5 with “Buy” rating. As per Tuesday, January 2, the company rating was maintained by Piper Jaffray.

More notable recent Vericel Corporation (NASDAQ:VCEL) news were published by: which released: “Vericel to Report Fourth-Quarter and Full-Year 2017 Financial Results on March …” on February 22, 2018, also with their article: “Vericel to Present at BioCentury’s 25th Annual Future Leaders in the Biotech …” published on March 09, 2018, published: “World Champion Swimmer and Twelve-Time Medalist Dara Torres Partners with …” on March 05, 2018. More interesting news about Vericel Corporation (NASDAQ:VCEL) were released by: and their article: “Vericel to Present at the 17th Annual Needham Healthcare Conference” published on March 13, 2018 as well as‘s news article titled: “Vericel Corp. (VCEL) Has Climbed To A New High Following Q4 Report” with publication date: March 05, 2018.

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, makes, markets, and sells patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company has market cap of $406.68 million. It markets three autologous cell therapy products, including Carticel and MACI, which are used for the treatment of cartilage defects in the knee; and Epicel, a permanent skin replacement that is used for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area in the United States. It currently has negative earnings. The firm also develops ixmyelocel-T, which is in Phase IIb clinical trial, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: